Akzo Nobel N.V. — M&A Activity 2007

Oct 12, 2007

Akzo Nobel confirms OBS sale on schedule

Amsterdam, the Netherlands, October 11, 2007 – Schering-Plough Corporation has received approval from the European Commission for its planned acquisition of Organon BioSciences N.V. from Akzo Nobel N.V.

In connection with the clearance, Schering-Plough has agreed to divest certain animal health products in Europe. The divestitures are not material to the company's financial results. No divestitures of human health products are required.

The EUR 11 billion deal was announced in March and Schering-Plough still needs to secure certain regulatory approvals, including clearance from the U.S. Federal Trade Commission (FTC), before the transaction can be finalized.

Both Akzo Nobel and Schering-Plough continue to expect the deal to be completed by the end of the year.

---

Note to editors

Akzo Nobel is a Fortune Global 500 company and is listed on Euronext Amsterdam. It is also the Chemicals Industry leader on the Dow Jones Sustainability Indexes and Akzo Nobel is included on the FTSE4Good Index. Based in the Netherlands, we are a multicultural organization serving customers throughout the world with coatings, chemicals and human and animal healthcare products. We employ around 62,000 people and conduct our activities in these four segments, with operating subsidiaries in more than 80 countries. Consolidated revenues for 2006 totaled EUR 13.7 billion. The financial results for the third quarter will be published on October, 23, 2007.

Internet: www.akzonobel.com

Not for publication – for more information

Akzo Nobel N.V. Corporate Media Relations, tel. +31 20 502 7833 Contact: Heleen van de Lustgraaf

Safe Harbor Statement*

This press release may contain statements which address such key issues as Akzo Nobel's growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals. Such statements should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to, price fluctuations, currency fluctuations, progress of drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies. For a more comprehensive discussion of the risk factors affecting our business please see our Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the company's corporate website www.akzonobel.com.

* Pursuant to the U.S. Private Securities Litigation Reform Act 1995.

Akzo Nobel nv Strawinskylaan 2555 P.O. Box 75730 1070 AS Amsterdam The Netherlands Tel.: +31 20 502 7833 Fax: +31 20 502 7604